AlloVir, Inc.
ALVR · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $3 | $1 |
| Gross Profit | $0 | -$0 | -$3 | -$1 |
| % Margin | – | – | – | – |
| R&D Expenses | $12 | $133 | $119 | $121 |
| G&A Expenses | $43 | $48 | $52 | $49 |
| SG&A Expenses | $43 | $48 | $52 | $49 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $10 | $0 | $0 | -$1 |
| Operating Expenses | $65 | $181 | $171 | $169 |
| Operating Income | -$65 | -$181 | -$171 | -$170 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $7 | -$9 | $2 | -$1 |
| Pre-Tax Income | -$59 | -$191 | -$169 | -$171 |
| Tax Expense | $0 | -$0 | -$0 | $1 |
| Net Income | -$59 | -$190 | -$169 | -$172 |
| % Margin | – | – | – | – |
| EPS | -11.73 | -42.09 | -50.6 | -63.02 |
| % Growth | 72.1% | 16.8% | 19.7% | – |
| EPS Diluted | -11.73 | -42.09 | -50.6 | -63.02 |
| Weighted Avg Shares Out | 5 | 4 | 3 | 3 |
| Weighted Avg Shares Out Dil | 5 | 4 | 3 | 3 |
| Supplemental Information | – | – | – | – |
| Interest Income | $5 | $6 | $2 | $1 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $3 | $1 |
| EBITDA | -$65 | -$190 | -$166 | -$170 |
| % Margin | – | – | – | – |